This cost is common for drug development. You may google the cost of bringing a drug to market. So you can understand how difficult to develop a new drug. The problems of PBT are low efficiencies and lack of communication. Now that they have a new CEO and we can see some changes accordingly, a game changing event is expected and realistic.
Commercialization of PBT2 as antibiotics still needs more research and clinical data. It is not an easy job but can be faster if they have a good partner. Its clinical trials can be more straightforward and expedited compared to neurodegenerative studies.
Currently the whole stock market is down. The share price could be consolidated here or halved from the peak. I am happy to accumulate more cheap shares. We should be able to hear some good news sooner or later.
Presentation today, page-5
-
- There are more pages in this discussion • 15 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
-0.001(11.1%) |
Mkt cap ! $20.98M | |||
| Open | High | Low | Value | Volume |
| 0.5¢ | 0.5¢ | 0.4¢ | $14.55K | 3.241M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 62 | 71906262 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 32338803 | 25 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| ATH (ASX) Chart |